Vo Trung Quang, Nguyen Hieu Minh, Thai Tinh Huu, La Van Ngoc, Truong Quoc Ky
Department of Economic and Administrative Pharmacy, Pham Ngoc Thach University of Medicine, Ho Chi Minh City, Vietnam.
Department of Pharmacy, Military Hospital 175.
J Pak Med Assoc. 2019 Jun;69(Suppl 2)(6):S41-S48.
Asthma is a disease that causes significant health and economic burdens worldwide. The prevalence and incidence of asthma have been rising around the world over recent decades. The current study is to capture the direct medical costs of inpatient and outpatient asthma treatment for the period from 2013 to 2017.
This study was conducted at Military Hospital 175 in Vietnam. The study was performed from the patient and social insurance perspective, which means all types of costs were identified and measured based on patients' healthcare insurance. Cost analysis was measured using the medical records for estimating the economic burden of asthma. The study adopted descriptive statistics and bootstrap techniques to calculate asthma-related costs as well as analyze the background characteristics of asthma patients.
The average outpatient and inpatient costs were US$64.90 and US$141.20, respectively, over the period from 2013 to 2017, for which out-of-pocket payments accounted for 10-12%. Medications, specifically asthma controller drugs, were the key driver leading to the substantial burden of direct medical costs for treating asthma. The cost burden was also significantly higher for adult patients compared to children.
Asthma continues to be a concerning problem in Vietnam. The economic impact of either preventive or promotive health interventions that can reduce the prevalence of asthma can be predicted from the statistics found in this research. Moreover, this data will help policymakers plan and allocate national expenditures for asthma treatment in a more rational way.
哮喘是一种在全球范围内造成重大健康和经济负担的疾病。近几十年来，全球哮喘的患病率和发病率一直在上升。本研究旨在获取2013年至2017年期间哮喘住院和门诊治疗的直接医疗费用。
本研究在越南第175军事医院进行。该研究从患者和社会保险的角度进行，这意味着所有类型的费用都是根据患者的医疗保险来确定和衡量的。使用病历进行成本分析以估计哮喘的经济负担。该研究采用描述性统计和自助抽样技术来计算与哮喘相关的费用，并分析哮喘患者的背景特征。
2013年至2017年期间，门诊和住院的平均费用分别为64.90美元和141.20美元，其中自付费用占10 - 12%。药物，特别是哮喘控制药物，是导致哮喘治疗直接医疗费用负担沉重的主要驱动因素。与儿童相比，成年患者的费用负担也明显更高。
哮喘在越南仍然是一个令人担忧的问题。从本研究中的统计数据可以预测，任何能够降低哮喘患病率的预防性或促进性健康干预措施的经济影响。此外，这些数据将有助于政策制定者更合理地规划和分配国家用于哮喘治疗的支出。
